| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041909584 |
| P356 | DOI | 10.1007/S11936-014-0346-X |
| P698 | PubMed publication ID | 25193559 |
| P50 | author | Wendy S. Post | Q102265913 |
| P2093 | author name string | Todd T Brown | |
| Thomas S Metkus | |||
| P2860 | cites work | Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement | Q22241128 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| HIV infection and the risk of acute myocardial infarction | Q27347231 | ||
| The DASH diet for high blood pressure: from clinical trial to dinner table | Q28287424 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy | Q29616232 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q29620108 | ||
| High prevalence of peripheral arterial disease in HIV-infected persons | Q33317029 | ||
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 | ||
| Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study | Q33632786 | ||
| Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. | Q33690814 | ||
| Decline in the AIDS and death rates in the EuroSIDA study: an observational study | Q33967061 | ||
| Associations between HIV infection and subclinical coronary atherosclerosis | Q34085805 | ||
| HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study | Q34355660 | ||
| n-3 fatty acids in patients with multiple cardiovascular risk factors | Q34651597 | ||
| Food insecurity and other poverty indicators among people living with HIV/AIDS: effects on treatment and health outcomes | Q34742623 | ||
| Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | Q34983265 | ||
| A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario | Q35093858 | ||
| Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial | Q35101789 | ||
| Factors associated with D-dimer levels in HIV-infected individuals | Q35120065 | ||
| Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. | Q35160580 | ||
| Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients | Q35465943 | ||
| The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use | Q35556761 | ||
| Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients | Q35903682 | ||
| Management of the metabolic effects of HIV and HIV drugs | Q36021411 | ||
| Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies | Q36154208 | ||
| Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. | Q36377944 | ||
| Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City | Q36597220 | ||
| Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. | Q36661756 | ||
| Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study | Q36875697 | ||
| Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system | Q36894824 | ||
| Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death | Q36956948 | ||
| Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. | Q37016796 | ||
| Arterial inflammation in patients with HIV. | Q37046942 | ||
| Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women | Q37272371 | ||
| Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort | Q37274054 | ||
| Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 | ||
| Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications | Q37602891 | ||
| Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men. | Q37667660 | ||
| Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy | Q37671955 | ||
| Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis | Q37969727 | ||
| The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care | Q38023235 | ||
| HIV and coronary heart disease: time for a better understanding | Q38078094 | ||
| Human immunodeficiency virus: what primary care clinicians need to know | Q38167419 | ||
| Biologic aging, frailty, and age-related disease in chronic HIV infection | Q38212714 | ||
| Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients | Q42228871 | ||
| Effects of combined exercise training on immunological, physical and biochemical parameters in individuals with HIV/AIDS. | Q42252177 | ||
| Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers | Q42641504 | ||
| Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study | Q43063917 | ||
| Combination antiretroviral therapy and the risk of myocardial infarction | Q44662157 | ||
| Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection | Q44801351 | ||
| Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection | Q45729086 | ||
| The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. | Q46070290 | ||
| Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial | Q46765423 | ||
| HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. | Q50551836 | ||
| The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. | Q51943315 | ||
| HIV provider-patient communication regarding cardiovascular risk: results from the AIDS Treatment for Life International Survey. | Q53091708 | ||
| Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. | Q53608173 | ||
| Protease inhibitors and cardiovascular outcomes in patients with HIV-1 | Q57955538 | ||
| The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals | Q63367975 | ||
| Severe premature coronary artery disease with protease inhibitors | Q74716256 | ||
| 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q86757444 | ||
| P433 | issue | 11 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 346 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Current treatment options in cardiovascular medicine | Q27714743 |
| P1476 | title | Cardiovascular disease associated with the human immunodeficiency virus: an update | |
| P478 | volume | 16 |
| Q57132197 | Functional capacity and ventilatory efficiency are preserved in well-controlled people living with human immunodeficiency virus/acquired immunodeficiency syndrome |
| Q34412603 | Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis. |
| Q36187629 | Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy |
Search more.